Cue Biopharma, Inc. announced members of their management and scientific teams will participate in two scientific conferences this September, The Promise of Interleukin-2 Therapy taking place September 14-17 in Paris, France and the Next Generation Protein Therapeutics Summit, held in Boston, Massachusetts and virtually on September 28-30.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today members of their management and scientific teams will participate in two scientific conferences this September, The Promise of Interleukin-2 Therapy taking place September 14-17 in Paris, France and the Next Generation Protein Therapeutics Summit, held in Boston, Massachusetts and virtually on September 28-30.
Presentation Details
The Promise of IL-2 Therapy
Location: Centre international de Conférence Sorbonne Université, Paris, France
Presentation title: Leveraging the Immuno-STAT platform to enhance anti-tumor immunity by selectively delivering IL-2 to tumor-specific T cells
Presenter: Matteo Levisetti, M.D., senior vice president, Clinical Development, Cue Biopharma
Session: Session IX – IL-2 in Cancer Therapy
Date and time: September 17, 2022, 9:00 am CET
Dr. Levisetti will present an overview of Cue Biopharma’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform including the interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells. The presentation will highlight data from clinical trials evaluating CUE-101, the company’s lead clinical candidate from the CUE-100 series, in patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) as a monotherapy and in combination with pembrolizumab. Dr. Levisetti will also discuss the company’s second clinical candidate, CUE-102, currently in evaluation in a Phase 1 trial for patients with Wilms’ Tumor 1 (WT1)-positive cancers as well as other platform developments that support versatility for the potential treatment of several diverse cancers.
Presentation title: CUE-401: a novel IL-2/TGF-beta fusion protein for induction and expansion of regulatory T cells
Presenter: Steven Quayle, Ph.D., vice president Translational Pharmacology, Translational Medicine, Cue Biopharma
Session: Session X – Novel IL-2s and Combination Therapies
Date and time: September 17, 2022, 11:30 am CET
Dr. Quayle will provide an overview on the Company’s lead CUE-400 series drug product candidate CUE-401, a novel bispecific molecule designed for differentiation and expansion of induced regulatory T cells (iTregs). Dr. Quayle will discuss preclinical data supporting CUE-401’s mechanism of action and potential opportunity for the treatment of patients with autoimmune and graft-versus-host disease. Cue Biopharma plans to advance the CUE-400 series programs through strategic partnerships.
Presentation Details
Next Generation Protein Therapeutics Summit
Location: Boston Convention and Exhibition Center & virtual. The event will be simultaneously live streamed: https://informaconnect.com/next-gen-protein/
Presentation title: Immuno-STATs: TCR-selective engagers and activators of anti-tumor T cells
Presenter: Anish Suri, President and chief scientific officer, Cue Biopharma
Session: T Cell Engager Design and Challenges
Date and time: September 28, 2022, 4:30 pm ET
Dr. Suri will present an overview of Cue Biopharma’s Immuno-STAT platform and biologics designed to present tumor-specific proteins to T cell receptors (TCR) of the target tumor-specific T cells, to modulate that T cell repertoire for the anti-cancer response, as well as clinical data demonstrating the single-agent anti-tumor activity of CUE-101, the Company’s first IL-2 based clinical candidate, in late-stage head and neck cancer patients.
About Immuno-STAT
The company’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a pMHC to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells. The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation. Because our drug candidates are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body to transform the treatment of cancer. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the company’s estimate of the period in which it expects to have cash to fund its operations; the company’s belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; operations and clinical the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Maya Romanchuk
LifeSci Communications
mromanchuk@lifescicomms.com
